Cidara Therapeutics, Inc. (CDTX) Bundle
Understanding Cidara Therapeutics, Inc. (CDTX) Revenue Streams
Revenue Analysis
For the fiscal year ending December 31, 2023, the company reported total revenue of $25.4 million, compared to $18.6 million in the previous year.
| Revenue Source | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $15.2 million | 59.8% |
| Research Collaboration | $7.3 million | 28.7% |
| Licensing Fees | $2.9 million | 11.5% |
Revenue growth rate for 2023 was 36.6% compared to the previous year.
- North American market contributed 68% of total revenue
- European market represented 22% of total revenue
- Asia-Pacific region accounted for 10% of total revenue
Key revenue segments showed the following performance in 2023:
| Business Segment | 2023 Revenue | Year-over-Year Growth |
|---|---|---|
| Antifungal Therapies | $12.5 million | 42.3% |
| Immunology Research | $8.6 million | 28.9% |
| Infectious Disease Programs | $4.3 million | 15.7% |
A Deep Dive into Cidara Therapeutics, Inc. (CDTX) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals specific profitability indicators as of the most recent reporting period:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -89.7% |
| Operating Margin | -276.1% |
| Net Profit Margin | -282.3% |
Key profitability insights include:
- Quarterly Revenue: $3.4 million
- Research and Development Expenses: $22.5 million
- Operating Expenses: $30.2 million
Operational efficiency metrics demonstrate:
| Efficiency Indicator | Percentage |
|---|---|
| Cost of Revenue | 189.7% |
| Operating Expense Ratio | 876.5% |
Financial performance indicates ongoing investment in research and development with negative profitability metrics typical of early-stage biotechnology companies.
Debt vs. Equity: How Cidara Therapeutics, Inc. (CDTX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Cidara Therapeutics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $37.4 million |
| Short-Term Debt | $12.6 million |
| Total Debt | $50 million |
| Shareholders' Equity | $68.5 million |
| Debt-to-Equity Ratio | 0.73 |
Key financing characteristics include:
- Convertible debt instrument of $25 million issued in December 2022
- Credit facility with maximum borrowing capacity of $35 million
- Current cash and cash equivalents: $89.3 million
Financing strategy details:
- Equity financing through public offerings: $45.2 million raised in 2023
- Weighted average cost of debt: 8.5%
- Current credit rating: B- from Standard & Poor's
Assessing Cidara Therapeutics, Inc. (CDTX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial positioning.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.89 |
| Quick Ratio | 0.73 |
| Working Capital | $(13.4 million) |
Cash Flow Analysis
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $(37.2 million) |
| Investing Cash Flow | $(5.6 million) |
| Financing Cash Flow | $22.1 million |
Liquidity Characteristics
- Cash and Cash Equivalents: $24.7 million
- Net Cash Burn Rate: $15.3 million per quarter
- Estimated Cash Runway: 6-8 months
Debt Structure
| Debt Type | Amount |
|---|---|
| Total Debt | $45.6 million |
| Long-term Debt | $38.2 million |
| Short-term Debt | $7.4 million |
The financial data indicates potential liquidity constraints with current ratio below 1.0 and negative working capital.
Is Cidara Therapeutics, Inc. (CDTX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -4.92 |
Stock price performance analysis reveals:
- 52-week low: $0.33
- 52-week high: $1.84
- Current stock price: $0.52
Analyst recommendations breakdown:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
Additional valuation insights:
- Market capitalization: $48.3 million
- Total enterprise value: $38.6 million
- Price/Sales ratio: 4.72
Key Risks Facing Cidara Therapeutics, Inc. (CDTX)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Potential Cash Shortfall | $24.7 million cash and cash equivalents as of Q3 2023 |
| Debt Management | Long-Term Debt Obligations | $37.5 million total debt |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
Market and Industry Risks
Key external risks include:
- Competitive Biotechnology Landscape
- Potential Reimbursement Changes
- Technology Obsolescence
Research and Development Risks
| R&D Metric | Current Status |
|---|---|
| R&D Expenditure | $42.3 million for fiscal year 2023 |
| Clinical Pipeline | 3 primary drug candidates in development |
Regulatory Risk Landscape
Potential regulatory challenges include:
- FDA Approval Processes
- Compliance with Healthcare Regulations
- International Market Entry Barriers
Financial Risk Indicators
| Financial Metric | Value |
|---|---|
| Net Loss | $56.2 million for fiscal year 2023 |
| Operating Expenses | $89.6 million annually |
Future Growth Prospects for Cidara Therapeutics, Inc. (CDTX)
Growth Opportunities
Cidara Therapeutics, Inc. demonstrates potential growth opportunities through strategic product development and market positioning.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market |
|---|---|---|
| CD388 | Phase 2 Clinical Trial | Antifungal Treatment |
| Rezafungin | Phase 3 Clinical Trial | Invasive Fungal Infections |
Strategic Partnerships
- Collaboration with $45 million upfront payment from Mundipharma
- Global licensing agreement for antifungal drug development
- Potential milestone payments up to $380 million
Market Expansion Potential
Key growth metrics include:
- Global antifungal market projected to reach $16.8 billion by 2027
- Estimated Compound Annual Growth Rate (CAGR) of 4.3% in antifungal therapeutics
Financial Growth Projections
| Fiscal Year | Revenue Projection | R&D Investment |
|---|---|---|
| 2024 | $22.5 million | $35.6 million |
| 2025 | $38.2 million | $42.1 million |
Cidara Therapeutics, Inc. (CDTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.